jnj-64140284
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 30, 2017 (NCT03180762)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
GRIP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj-64140284
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04566926 | Phase 1 | Sep 29, 2020 | Janssen Pharmaceutica NV |
| NCT04033458 | Phase 1 | Jul 31, 2019 | Janssen Pharmaceutica NV |
| NCT03693391 | Phase 1 | Oct 17, 2018 | Johnson and Johnson |
| NCT03180762 | Phase 1 | May 30, 2017 | Johnson and Johnson |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2019 |
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2017 |
2 organizations
Page 1 / 1